---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-108179"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T23:05:07.447128+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MetaVia Phase 2a vanoglipel shows HbA1c -0.54%p, ALT reductions in MASH trial

## Summary
- At Week 16, vanoglipel monotherapy reduced HbA1c by 0.54%p and combination therapy by 0.66%p from baseline 6.99% (p<0.05 vs placebo).
- Vanoglipel significantly decreased plasma ALT in patients with baseline ALT 40-200 U/L, with hepatoprotective effects driven by monotherapy.
- Improvements in liver steatosis (CAP), stiffness (VCTE), and non-invasive scores (FAST, NIS-4) were observed at 16 weeks.
- Circulating biomarkers of cell death (CK18F/M30), inflammation (hs-CRP, CCL2), and fibrosis (TIMP1) were reduced.
- Vanoglipel 100 mg reduced pathogenic glycerolipids and glycerophospholipids; well tolerated with no discontinuations except one placebo.

## SEC filing metadata
- accession: 0001104659-25-108179
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465925108179/0001104659-25-108179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465925108179/mtva-20251107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-108179
- JSON: https://secwatch.observer/filing/0001104659-25-108179.json
- Plain text: https://secwatch.observer/filing/0001104659-25-108179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.